|
| Generic Available |
|
No |
 |
| Pharmacological Index |
|
Vaccine |
|
| Use |
|
Recommended for individuals who may come in contact with animal products which come from anthrax endemic areas and may be contaminated with Bacillus anthracis spores; recommended for high-risk persons such as veterinarians and other handling potentially infected animals. Routine immunization for the general population is not recommended. |
|
| Pregnancy Risk Factor |
|
C |
|
| Adverse Reactions |
|
>10%: Local: Mild reactions 1% to 10%: Local: Moderate reactions with inflammation and pruritus, subcutaneous nodules; all local reactions have been reversible <1%: Central nervous system: Malaise, chills, fever, lassitude |
|
| Stability |
|
Store in refrigerator, do not freeze |
|
| Mechanism of Action |
|
Active immunization against Bacillus anthracis |
|
| Usual Dosage |
|
Primary immunization: S.C.: Three injections of 0.5 mL each given 2 weeks apart followed by three additional S.C. injections given at 6, 12, and 18 months Subsequent booster injections: 0.5 mL at 1-year intervals are recommended for immunity to be maintained |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
No information available to require special precautions |
|
| Dental Health: Effects on Dental Treatment |
|
No effects or complications reported |
|
| Dosage Forms |
|
Injection: 5 mL (10 doses each) |
|
|
Copyright © 2007 Drugs Area |
